Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026

Why It Matters

The data positions ivodescimab as a potentially superior first‑line immunotherapy for squamous NSCLC, challenging the current pembrolizumab‑based standard and promising longer patient survival.

Key Takeaways

• Ivodescimab + chemo cut death risk 34% vs Tevimbra combo.
• Median overall survival extended to 27.9 months, 4.2 months longer.
• 24‑month OS rate reached 64.7%, outpacing 48.6% control.
• Progression‑free survival improved to 11.1 months versus 6.9 months.
• Subsequent immunotherapy use dropped to 13.9% from 19.2% control.

Pulse Analysis

The HARMONi‑6 Phase III trial marks a pivotal moment for squamous non‑small cell lung cancer, a subset that has lagged behind adenocarcinoma in therapeutic advances. By pairing ivodescimab, a novel PD‑1 inhibitor, with standard chemotherapy, Akeso achieved a statistically significant overall‑survival gain that exceeds the benchmark set by pembrolizumab‑based regimens. The 34% hazard reduction and a median OS extension of over four months signal a robust clinical benefit, especially given the consistency of results across PD‑L1 expression levels and metastatic burden.

From a clinical practice standpoint, the trial’s outcomes could reshape first‑line treatment algorithms. The improved progression‑free survival and higher long‑term survival rates suggest patients may experience delayed disease progression and reduced reliance on subsequent lines of therapy. Notably, fewer patients in the ivodescimab arm required later immunotherapy or targeted agents, indicating a more durable response. These findings are likely to accelerate regulatory submissions and could prompt guideline committees to reevaluate the preferred checkpoint inhibitor for squamous NSCLC.

For investors and the broader oncology market, Akeso’s success introduces a new competitor in a space dominated by a few large biotech firms. The data opens pathways for potential partnerships, licensing deals, or co‑development agreements, especially in regions where pembrolizumab faces pricing pressures. If approved, ivodescimab could generate substantial revenue streams, bolstering Akeso’s pipeline credibility and attracting further capital for its next‑generation immunotherapies.